Herve Hoppenot's most recent trade in Incyte Corp. was a trade of 2,843 Common Stock done at an average price of $96.7 . Disclosure was reported to the exchange on Dec. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Herve Hoppenot | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.70 per share. | 08 Dec 2025 | 2,843 | 326,803 (0%) | 0% | 96.7 | 274,918 | Common Stock |
| Incyte | Herve Hoppenot | Director | Sale of securities on an exchange or to another person at price $ 105.46 per share. | 10 Nov 2025 | 187,500 | 329,646 (0%) | 0% | 105.5 | 19,773,750 | Common Stock |
| Maze Therapeutics Inc | Herve Hoppenot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2025 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.98 per share. | 14 Jul 2025 | 4,961 | 521,859 (0%) | 0% | 70.0 | 347,171 | Common Stock |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.25 per share. | 14 Jul 2025 | 4,713 | 517,146 (0%) | 0% | 68.2 | 321,662 | Common Stock |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.17 per share. | 02 Jul 2025 | 42,769 | 526,820 (0%) | 0% | 68.2 | 2,915,563 | Common Stock |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 18,438 | 18,438 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 18,050 | 18,050 | - | - | Performance Shares | |
| Incyte | Herve Hoppenot | Director, Special Advisor to the CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 6,016 | 569,589 (0%) | 0% | 0 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 66,899 | 563,573 (0%) | 0% | 0 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 55,510 | 55,510 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 15 Jul 2024 | 61,189 | 61,189 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 15 Jul 2024 | 41,025 | 501,635 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 15 Jul 2024 | 4,961 | 496,674 (0%) | 0% | 64.2 | 318,744 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2024 | 41,723 | 460,610 (0%) | 0% | 59.0 | 2,462,491 | Common Stock | |
| Incyte | Hoppenot Herve | Director, Chairman / CEO, President | 14 Feb 2024 | 41,577 | 502,333 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Hoppenot Herve | Director, Chairman / CEO, President | 18 Jan 2024 | 97,566 | 97,566 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 14 Jul 2023 | 90,563 | 90,563 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 14 Jul 2023 | 43,184 | 434,856 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 03 Jul 2023 | 43,467 | 391,672 (0%) | 0% | 62.1 | 2,698,431 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 20 Jan 2023 | 86,449 | 86,449 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 20 Jan 2023 | 29,196 | 435,139 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2022 | 81,885 | 81,885 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2022 | 60,433 | 427,117 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2022 | 21,174 | 405,943 (0%) | 0% | 79.3 | 1,678,040 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 19 Jan 2022 | 84,852 | 84,852 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 19 Nov 2021 | 13,279 | 345,383 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 19 Nov 2021 | 2,227 | 332,104 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2021 | 84,851 | 84,851 | - | - | Employee Stock Option (right to buy) | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2021 | 44,264 | 347,528 (0%) | 0% | 0 | Common Stock | ||
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2021 | 16,089 | 331,439 (0%) | 0% | 83.6 | 1,344,719 | Common Stock | |
| Incyte | Herve Hoppenot | Director, Chairman / CEO, President | 02 Jul 2021 | 1,562 | 329,877 (0%) | 0% | 83.3 | 130,177 | Common Stock |